Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT)

被引:4
作者
Brown, Malcolm [1 ]
Murphy, Marie H. [2 ,3 ]
McAneney, Helen [4 ,5 ]
McBride, Ken [6 ]
Crawford, Ffiona [6 ]
Cole, Aidan [7 ,8 ]
O'Sullivan, Joe M. [7 ,8 ]
Jain, Suneil [7 ,8 ]
Prue, Gillian [1 ]
机构
[1] Queens Univ Belfast, Med Biol Ctr, Sch Nursing & Midwifery, 97 Lisburn Rd, Belfast BT9 7BL, North Ireland
[2] Ulster Univ, Ctr Exercise Med Phys Act & Hlth, Sch Sport, Belfast, North Ireland
[3] Univ Edinburgh, Sch Educ & Sport, Edinburgh, Scotland
[4] Ulster Univ, Sch Med, Northern Ireland Publ Hlth Res Network, Belfast, North Ireland
[5] Univ Coll Dublin, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland
[6] Northern Ireland Canc Res Consumer Forum, Belfast, North Ireland
[7] Belfast Hlth & Social Care Trust, Northern Ireland Canc Ctr, Belfast, North Ireland
[8] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, North Ireland
关键词
Exercise; Feasibility; Metastatic prostate cancer; Functional fitness; Health-related quality of life; QUALITY-OF-LIFE; DEPRIVATION THERAPY; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; PHYSICAL-ACTIVITY; MEN; ENZALUTAMIDE; STRENGTH; MECHANISMS; COUNTRIES;
D O I
10.1007/s00520-023-07894-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundExercise is an effective adjuvant therapy that can alleviate treatment-related toxicities for men with prostate cancer (PC). However, the feasibility of delivering exercise training to men with advanced disease and the wider impact on clinical outcomes remain unknown. The purpose of the EXACT trial was to determine the feasibility and effects of home-based exercise training in men with metastatic castrate-resistant prostate cancer (mCRPC).MethodsPatients with mCRPC receiving ADT + an androgen receptor pathway inhibitor (ARPI) were prescribed 12 weeks of home-based, remotely monitored, moderate intensity, aerobic and resistance exercise. Feasibility was assessed using recruitment, retention and adherence rates. Safety and adverse events were monitored throughout, with functional and patient-reported outcomes captured at baseline, post-intervention and at 3-month follow-up.ResultsFrom the 117 screened, 49 were deemed eligible and approached, with 30 patients providing informed consent (61% recruitment rate). Of those who consented, 28 patients completed baseline assessments, with 24 patients completing the intervention and 22 completing follow-up (retention rates: 86% and 79% respectively). Task completion was excellent throughout, with no intervention-related adverse events recorded. Self-reported adherence to the overall intervention was 82%. Exercise training decreased mean body mass (-1.5%), improved functional fitness (> 10%) and improved several patient-reported outcomes including clinically meaningful changes in fatigue (p = 0.042), FACT-G (p = 0.054) and FACT-P (p = 0.083), all with moderate effect sizes.ConclusionHome-based exercise training, with weekly remote monitoring, was feasible and safe for men with mCRPC being treated with an ARPI. Given that treatment-related toxicities accumulate throughout the course of treatment, and as a result, negatively impact functional fitness and health-related quality of life (HRQoL), it was positive that exercise training improved or prevented a decline in these clinically important variables and could better equip patients for future treatment. Collectively, these preliminary feasibility findings support the need for a definitive, larger RCT, which downstream may lead to the inclusion of home-based exercise training as part of adjuvant care for mCRPC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Effects of home-based exercise training on VO2 in breast cancer patients under adjuvant or neoadjuvant chemotherapy (SAPA): a randomized controlled trial
    Cornette, Thibault
    Vincent, Francois
    Mandigout, Stephane
    Antonini, Marie-Therese
    Leobon, Sophie
    Labrunie, Anais
    Venat, Laurence
    Lavau-Denes, Sandrine
    Tubiana-Mathieu, Nicole
    EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE, 2016, 52 (02) : 223 - 232
  • [42] Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
    Seguier, Denis
    Parent, Pauline
    Duterque-Coquillaud, Martine
    Labre, Julien
    Fromont-Hankard, Gaelle
    Dariane, Charles
    Penel, Nicolas
    Villers, Arnauld
    Turpin, Anthony
    Olivier, Jonathan
    EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02): : 581 - 590
  • [43] Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial
    Roy, Soumyajit
    Sun, Yilun
    Morgan, Scott C.
    Wallis, Christopher J. D.
    King, Kevin
    Zhou, Yu M.
    D'souza, Leah A.
    Azem, Omar
    Cueto-Marquez, Adrianna E.
    Camden, Nathaniel B.
    Spratt, Daniel E.
    Kishan, Amar U.
    Saad, Fred
    Malone, Shawn
    EUROPEAN UROLOGY, 2023, 83 (06) : 571 - 579
  • [44] A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
    Peer, Cody J.
    Schmidt, Keith T.
    Kindrick, Jessica D.
    Eisner, Joel R.
    Brown, Victoria V.
    Baskin-Bey, Edwina
    Madan, Ravi
    Figg, William D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 759 - 770
  • [45] Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors
    Machidori, Asako
    Shiota, Masaki
    Kobayashi, Satoshi
    Matsumoto, Takashi
    Monji, Keisuke
    Kashiwagi, Eiji
    Takeuchi, Ario
    Takahashi, Ryosuke
    Inokuchi, Junichi
    Eto, Masatoshi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (06) : 365.e1 - 365.e7
  • [46] 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
    Morris, Michael J.
    Castellano, Daniel
    Herrmann, Ken
    de Bono, Johann S.
    Shore, Neal D.
    Chi, Kim N.
    Crosby, Michael
    Piulats, Josep M.
    Flechon, Aude
    Wei, Xiao X.
    Mahammedi, Hakim
    Roubaud, Guilhem
    Studentova, Hana
    Nagarajah, James
    Mellado, Begona
    Montesa-Pino, Alvaro
    Kpamegan, Euloge
    Ghebremariam, Samson
    Kreisl, Teri N.
    Wilke, Celine
    Lehnhoff, Katja
    Sartor, Oliver
    Fizazi, Karim
    LANCET, 2024, 404 (10459) : 1227 - 1239
  • [47] The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer
    Naiki, Taku
    Takahara, Kiyoshi
    Watanabe, Hiromitsu
    Nakane, Keita
    Sugiyama, Yosuke
    Koie, Takuya
    Shiroki, Ryoichi
    Miyake, Hideaki
    Yasui, Takahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 164 - 171
  • [48] Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy
    Mellgard, George
    Saffran, Nathaniel
    Chakrani, Zakaria
    McCroskery, Stephen
    Taylor, Nicole
    Patel, Mann
    Liaw, Bobby
    Galsky, Matthew
    Oh, William
    Tsao, Che-Kai
    Patel, Vaibhav
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (10): : 459 - 464
  • [49] Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
    Yamamoto, Yutaka
    Fujimoto, Saizo
    Hashimoto, Mamoru
    Minami, Takafumi
    Fukuokaya, Wataru
    Yanagisawa, Takafumi
    Saruta, Masanobu
    Takahara, Kiyoshi
    Nishimura, Kazuki
    Tsujino, Takuya
    Nakamori, Yuta
    Hashimoto, Takeshi
    Kimura, Takahiro
    Shiroki, Ryoichi
    Azuma, Haruhito
    Ohno, Yoshio
    Fujita, Kazutoshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1946 - 1958
  • [50] Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
    Jensen, Jeffrey L.
    Bobek, Olivia
    Chan, Irenaeus C. C.
    Miller, Brian C.
    Hillman, David W.
    Heller, Glenn
    Druley, Todd
    Armstrong, Andrew J.
    Morris, Michael J.
    Milowsky, Matthew I.
    Beltran, Himisha
    Bolton, Kelly L.
    Coombs, Catherine C.
    CLINICAL CANCER RESEARCH, 2024, 30 (21) : 4910 - 4919